BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hajarizadeh B, Cunningham EB, Valerio H, Martinello M, Law M, Janjua NZ, Midgard H, Dalgard O, Dillon J, Hickman M, Bruneau J, Dore GJ, Grebely J. Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysis. Journal of Hepatology 2020;72:643-57. [DOI: 10.1016/j.jhep.2019.11.012] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 13.5] [Reference Citation Analysis]
Number Citing Articles
1 Tamori A, Uchida-Kobayashi S, Kozuka R, Motoyama H, Yoshida K, Odagiri N, Kotani K, Kawamura E, Fujii H, Hagihara A, Enomoto M, Kawada N. High dropout rate from aftercare program of antihepatitis C therapy for patients with history of injection drug use. JGH Open 2020;4:964-9. [PMID: 33102771 DOI: 10.1002/jgh3.12376] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Chevaliez S, Wlassow M, Volant J, Roudot-Thoraval F, Bachelard A, Poiteau L, Trabut JB, Hézode C, Bourdel A, Dominguez S. Assessing Molecular Point-of-Care Testing and Dried Blood Spot for Hepatitis C Virus Screening in People Who Inject Drugs. Open Forum Infect Dis 2020;7:ofaa196. [PMID: 32617372 DOI: 10.1093/ofid/ofaa196] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
3 Liu CH, Peng CY, Kao WY, Yang SS, Shih YL, Lin CL, Tsai MK, Lee CY, Chang CC, Wu JH, Liu CJ, Su TH, Tseng TC, Chen PJ, Kao JH. Hepatitis C virus reinfection in patients on haemodialysis after achieving sustained virologic response with antiviral treatment. Aliment Pharmacol Ther 2021. [PMID: 34773272 DOI: 10.1111/apt.16697] [Reference Citation Analysis]
4 Selfridge M, Barnett T, Lundgren K, Guarasci K, Milne R, Drost A, Fraser C. Treating people where they are: Nurse-led micro-elimination of hepatitis C in supported housing sites for networks of people who inject drugs in Victoria, Canada. Public Health Nurs 2022. [PMID: 35537120 DOI: 10.1111/phn.13092] [Reference Citation Analysis]
5 Townshend-Bulson L, Roik E, Barbour Y, Bruden DJT, Homan CE, Espera HGF, Stevenson TJ, Hewitt AM, Rhodes W, Gove JE, Plotnik JN, Snowball MM, McGilvray J, Simons BC, Johnston JM, McMahon BJ. The Alaska Native/American Indian experience of hepatitis C treatment with sofosbuvir-based direct-acting antivirals. PLoS One 2021;16:e0260970. [PMID: 34855920 DOI: 10.1371/journal.pone.0260970] [Reference Citation Analysis]
6 Minosse C, Gruber CEM, Rueca M, Taibi C, Zaccarelli M, Grilli E, Montalbano M, Capobianchi MR, Antinori A, D'Offizi G, McPhee F, Garbuglia AR. Late Relapse and Reinfection in HCV Patients Treated with Direct-Acting Antiviral (DAA) Drugs. Viruses 2021;13:1151. [PMID: 34208646 DOI: 10.3390/v13061151] [Reference Citation Analysis]
7 Yang X, Tang Y, Xu D, Zhang G, Xu P, Tang H, Pang L. Efficacy and safety of ledipasvir/sofosbuvir for hepatitis C among drug users: a systematic review and meta-analysis. Virol J 2021;18:156. [PMID: 34315488 DOI: 10.1186/s12985-021-01625-w] [Reference Citation Analysis]
8 Jiang X, Parker RL, Vouri SM, Lo-Ciganic W, Diaby V, Henry L, Park H. Cascade of Hepatitis C Virus Care Among Patients With Substance Use Disorders. Am J Prev Med 2021:S0749-3797(21)00271-3. [PMID: 34210584 DOI: 10.1016/j.amepre.2021.04.013] [Reference Citation Analysis]
9 Fadnes LT, Aas CF, Vold JH, Leiva RA, Ohldieck C, Chalabianloo F, Skurtveit S, Lygren OJ, Dalgård O, Vickerman P, Midgard H, Løberg EM, Johansson KA; INTRO-HCV Study Group. Integrated treatment of hepatitis C virus infection among people who inject drugs: A multicenter randomized controlled trial (INTRO-HCV). PLoS Med 2021;18:e1003653. [PMID: 34061883 DOI: 10.1371/journal.pmed.1003653] [Reference Citation Analysis]
10 Grebely J, Collins AB, Artenie AA, Sutherland R, Meyer JP, Barocas JA, Falade-Nwulia O, Cepeda JA, Cunningham EB, Hajarizadeh B, Lafferty L, Lazarus JV, Bonn M, Marshall AD, Treloar C. Progress and remaining challenges to address hepatitis C, other infectious diseases, and drug-related harms to improve the health of people who use drugs. Int J Drug Policy 2021;96:103469. [PMID: 34610884 DOI: 10.1016/j.drugpo.2021.103469] [Reference Citation Analysis]
11 Cheng CY, Ku SY, Lin YC, Chen CP, Cheng SH, Lin IF. Incidence and Risk Factors of Reinfection with HCV after Treatment in People Living with HIV. Viruses 2022;14:439. [PMID: 35216032 DOI: 10.3390/v14020439] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Chichetto NE, Polanka BM, So-Armah KA, Sung M, Stewart JC, Koethe JR, Edelman EJ, Tindle HA, Freiberg MS. Contribution of Behavioral Health Factors to Non-AIDS-Related Comorbidities: an Updated Review. Curr HIV/AIDS Rep 2020;17:354-72. [PMID: 32314325 DOI: 10.1007/s11904-020-00498-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
13 Midgard H, Ulstein K, Backe Ø, Foshaug T, Sørli H, Vennesland K, Nilssen D, Dahl EH, Finbråten AK, Wüsthoff L, Dalgard O. Hepatitis C treatment and reinfection surveillance among people who inject drugs in a low-threshold program in Oslo, Norway. Int J Drug Policy 2021;:103165. [PMID: 33642182 DOI: 10.1016/j.drugpo.2021.103165] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Yeung A, Palmateer NE, Dillon JF, McDonald SA, Smith S, Barclay S, Hayes PC, Gunson RN, Templeton K, Goldberg DJ, Hickman M, Hutchinson SJ. Population-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among people who inject drugs. J Hepatol 2021:S0168-8278(21)02103-6. [PMID: 34634387 DOI: 10.1016/j.jhep.2021.09.038] [Reference Citation Analysis]
15 Rinaldi L, Messina V, Di Marco V, Iovinella V, Claar E, Cariti G, Sacco R, De Luca M, Scifo G, Gatti P, Barbarini G, Pace Palitti V, Quartini M, Tundo P, D'Offizi G, Parruti G, di Rosolini MA, Garrucciu G, Cosco L, Benanti F, Gimignani G, Vespasiani Gentilucci U, Di Lorenzo F, D'Antò M, Nevola R, Lupia T, Rosato V, Morbiducci V, Luzzitelli I, Sozio F, Di Stefano M, Ciraci E, Bulla F, Guarisco R, Cangiano C, Imparato M, Maggi P, Ascione A, Craxì A, Izzi A. Factors Enhancing Treatment of Hepatitis C Virus-Infected Italian People Who Use Drugs: The CLEO-GRECAS Experience. Am J Gastroenterol 2021;116:1248-55. [PMID: 34074828 DOI: 10.14309/ajg.0000000000001147] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Harney BL, Brereton R, Whitton B, Pietrzak D, Paige E, Roberts SK, Birks S, Saraf S, Hellard ME, Doyle JS. Hepatitis C treatment in a co-located mental health and alcohol and drug service using a nurse-led model of care. J Viral Hepat 2021;28:771-8. [PMID: 33599036 DOI: 10.1111/jvh.13487] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
17 Haque LY, Fiellin DA. Bridging the Gap: Dual Fellowship Training in Addiction Medicine and Digestive Diseases. Dig Dis Sci. [DOI: 10.1007/s10620-022-07478-9] [Reference Citation Analysis]
18 Valerio H, Alavi M, Conway A, Silk D, Treloar C, Martinello M, Milat A, Dunlop A, Murray C, Henderson C, Amin J, Read P, Marks P, Degenhardt L, Stevens A, Prain B, Hayllar J, Reid D, Montebello M, Wade A, Christmass M, Cock V, Dore GJ, Grebely J. Declining prevalence of current HCV infection and increased treatment uptake among people who inject drugs: The ETHOS Engage study. International Journal of Drug Policy 2022;105:103706. [DOI: 10.1016/j.drugpo.2022.103706] [Reference Citation Analysis]
19 Habchi J, Thomas AM, Sprecht-Walsh S, Arias E, Bratberg J, Hurley L, Hart S, Taylor LE. Optimizing Hepatitis C Virus (HCV) Treatment in a US Colocated HCV/Opioid Agonist Therapy Program. Open Forum Infect Dis 2020;7:ofaa310. [PMID: 33072802 DOI: 10.1093/ofid/ofaa310] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
20 Liu C, Kao J. Last Mile to Microelimination of Hepatitis C Virus Infection Among People Living With Human Immunodeficiency Virus. Clinical Infectious Diseases 2021;73:e2172-4. [DOI: 10.1093/cid/ciaa1499] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
21 Foschi FG, Borghi A, Grassi A, Lanzi A, Speranza E, Vignoli T, Napoli L, Olivoni D, Sanza M, Polidori E, Greco G, Bassi P, Cristini F, Ballardini G, Altini M, Conti F, On Behalf Of Mith Group. Model of Care for Microelimination of Hepatitis C Virus Infection among People Who Inject Drugs. J Clin Med 2021;10:4001. [PMID: 34501448 DOI: 10.3390/jcm10174001] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Busschots D, Bielen R, Koc ÖM, Heyens L, Verrando R, de Galocsy C, Van Steenkiste C, Nevens F, Midgard H, Dalgard O, Robaeys G. Hepatitis C reinfection in former and active injecting drug users in Belgium. Harm Reduct J 2021;18:102. [PMID: 34641896 DOI: 10.1186/s12954-021-00552-x] [Reference Citation Analysis]
23 Muller A, Vlahov D, Akiyama MJ, Kurth A. Hepatitis C Reinfection in People Who Inject Drugs in Resource-Limited Countries: A Systematic Review and Analysis. Int J Environ Res Public Health 2020;17:E4951. [PMID: 32659974 DOI: 10.3390/ijerph17144951] [Reference Citation Analysis]
24 Schmidbauer C, Schwarz M, Schütz A, Schubert R, Schwanke C, Gutic E, Pirker R, Lang T, Reiberger T, Haltmayer H, Gschwantler M. Directly observed therapy at opioid substitution facilities using sofosbuvir/velpatasvir results in excellent SVR12 rates in PWIDs at high risk for non-adherence to DAA therapy. PLoS One 2021;16:e0252274. [PMID: 34086708 DOI: 10.1371/journal.pone.0252274] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Sun HY, Cheng CY, Lin CY, Yang CJ, Lee NY, Liou BH, Tang HJ, Liu YM, Lee CY, Chen TC, Huang YC, Lee YT, Tsai MJ, Lu PL, Tsai HC, Wang NC, Hung TC, Cheng SH, Hung CC. Real-world effectiveness of direct-acting antivirals in people living with human immunodeficiency virus and hepatitis C virus genotype 6 infections. World J Gastroenterol 2022; 28(11): 1172-1183 [DOI: 10.3748/wjg.v28.i11.1172] [Reference Citation Analysis]
26 Trooskin SB, Dore G, Kostman J. We Must Do Better: Addressing HCV Treatment Barriers in Persons Who Inject Drugs in the United States. J Infect Dis 2020;222:S773-81. [PMID: 33245349 DOI: 10.1093/infdis/jiaa574] [Reference Citation Analysis]
27 Byrne CJ, Beer L, Inglis SK, Robinson E, Radley A, Goldberg DJ, Hickman M, Hutchinson S, Dillon JF. Real-world outcomes of rapid regional hepatitis c virus treatment scale-up among people who inject drugs in Tayside, Scotland. Aliment Pharmacol Ther 2021. [PMID: 34877667 DOI: 10.1111/apt.16728] [Reference Citation Analysis]
28 Carson JM, Hajarizadeh B, Hanson J, O'Beirne J, Iser D, Read P, Balcomb A, Davies J, Doyle JS, Yee J, Martinello M, Marks P, Dore GJ, Matthews GV; REACH-C Study Group. Effectiveness of treatment for hepatitis C virus reinfection following direct acting antiviral therapy in the REACH-C cohort. Int J Drug Policy 2021;96:103422. [PMID: 34426040 DOI: 10.1016/j.drugpo.2021.103422] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Huang P, Wang Y, Yue M, Ge Z, Xia X, Jeyarajan AJ, Holmes JA, Yu R, Zhu C, Yang S, Lin W, Chung RT. The risk of hepatitis C virus recurrence in hepatitis C virus-infected patients treated with direct-acting antivirals after achieving a sustained virological response: A comprehensive analysis. Liver Int 2021. [PMID: 34051040 DOI: 10.1111/liv.14976] [Reference Citation Analysis]
30 Wood S, Harrison SE, Judd N, Bellis MA, Hughes K, Jones A. The impact of behavioural risk factors on communicable diseases: a systematic review of reviews. BMC Public Health 2021;21:2110. [PMID: 34789209 DOI: 10.1186/s12889-021-12148-y] [Reference Citation Analysis]
31 Midgard H, Finbråten AK, Malme KB, Berg-Pedersen RM, Tanum L, Olsen IC, Bjørnestad R, Dalgard O. Opportunistic treatment of hepatitis C virus infection (OPPORTUNI-C): study protocol for a pragmatic stepped wedge cluster randomized trial of immediate versus outpatient treatment initiation among hospitalized people who inject drugs. Trials 2020;21:524. [PMID: 32539853 DOI: 10.1186/s13063-020-04434-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
32 Blomé MA, Bråbäck M, Alsterberg S, Jerkeman A. Hepatitis C treatment at a Swedish needle exchange program, a successful model of care - the ACTIONNE study. Int J Drug Policy 2021;:103407. [PMID: 34391622 DOI: 10.1016/j.drugpo.2021.103407] [Reference Citation Analysis]
33 Caven M, Baiano CX, Robinson EM, Stephens B, Macpherson I, Dillon JF. Hepatitis C reinfection by treatment pathway among people who inject drugs in Tayside, Scotland. J Viral Hepat 2021;28:1744-50. [PMID: 34525228 DOI: 10.1111/jvh.13614] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Selfridge M, Cunningham EB, Barnett T, Drost A, Gray-Schleihauf C, Guarasci K, Lundgren K, Milne R, Grebely J, Fraser C. Reinfection following successful direct-acting antiviral therapy for HCV infection among people attending an inner-city community health centre in Victoria, Canada. Int J Drug Policy 2021;96:103418. [PMID: 34538704 DOI: 10.1016/j.drugpo.2021.103418] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Wyles DL, Kang M, Matining RM, Murphy RL, Peters MG. Continued Low Rates of Hepatitis C Virus (HCV) Recurrence in HCV/HIV- and HCV-Infected Participants Who Achieved Sustained Virologic Response After Direct-Acting Antiviral Treatment: Final Results From the AIDS Clinical Trials Group A5320 Viral Hepatitis C Infection Long-term Cohort Study (V-HICS). Open Forum Infect Dis 2021;8:ofab511. [PMID: 34926713 DOI: 10.1093/ofid/ofab511] [Reference Citation Analysis]
36 Pawlotsky J, Negro F, Aghemo A, Berenguer M, Dalgard O, Dusheiko G, Marra F, Puoti M, Wedemeyer H. EASL recommendations on treatment of hepatitis C: Final update of the series☆. Journal of Hepatology 2020;73:1170-218. [DOI: 10.1016/j.jhep.2020.08.018] [Cited by in Crossref: 113] [Cited by in F6Publishing: 102] [Article Influence: 56.5] [Reference Citation Analysis]
37 Eckhardt B, Mateu-Gelabert P, Aponte-Melendez Y, Fong C, Kapadia S, Smith M, Edlin BR, Marks KM. Accessible Hepatitis C Care for People Who Inject Drugs: A Randomized Clinical Trial. JAMA Intern Med 2022. [PMID: 35285851 DOI: 10.1001/jamainternmed.2022.0170] [Reference Citation Analysis]
38 Lanièce Delaunay C, Godin A, Kronfli N, Panagiotoglou D, Cox J, Alary M, Klein MB, Maheu-Giroux M. Can hepatitis C elimination targets be sustained among people who inject drugs post-2030? Int J Drug Policy 2021;:103343. [PMID: 34215459 DOI: 10.1016/j.drugpo.2021.103343] [Reference Citation Analysis]
39 Seto MT, Cheung KW, Hung IFN. Management of viral hepatitis A, C, D and E in pregnancy. Best Pract Res Clin Obstet Gynaecol 2020;68:44-53. [PMID: 32305262 DOI: 10.1016/j.bpobgyn.2020.03.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
40 Phelps CC, Walker CM, Honegger JR. Where to Next? Research Directions after the First Hepatitis C Vaccine Efficacy Trial. Viruses 2021;13:1351. [PMID: 34372558 DOI: 10.3390/v13071351] [Reference Citation Analysis]
41 Kouroumalis E, Voumvouraki A. Hepatitis C virus: A critical approach to who really needs treatment. World J Hepatol 2022; 14(1): 1-44 [DOI: 10.4254/wjh.v14.i1.1] [Reference Citation Analysis]
42 Hajarizadeh B, Grebely J, Byrne M, Marks P, Amin J, McManus H, Butler T, Cunningham EB, Vickerman P, Martin NK, McHutchison JG, Brainard DM, Treloar C, Chambers GM, Grant L, Mcgrath C, Lloyd AR, Dore GJ; SToP-C study group. Evaluation of hepatitis C treatment-as-prevention within Australian prisons (SToP-C): a prospective cohort study. Lancet Gastroenterol Hepatol 2021;6:533-46. [PMID: 33965006 DOI: 10.1016/S2468-1253(21)00077-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
43 Chilaka VN, Konje JC. Viral Hepatitis in pregnancy. Eur J Obstet Gynecol Reprod Biol 2021;256:287-96. [PMID: 33259998 DOI: 10.1016/j.ejogrb.2020.11.052] [Reference Citation Analysis]
44 Conway B, Smyth D, Thomas R, Wong A, Sebastiani G, Cooper C, Shah H, Kumar R, Deutsch G, Watson T. Characterizing risk behaviour and reinfection rates for successful programs to engage core transmitters in HCV elimination (C-RESPECT). CanLivJ 2021;4:346-59. [DOI: 10.3138/canlivj-2021-0005] [Reference Citation Analysis]
45 Falcato L, Bernardini C, Bruggmann P. Hepatitis C reinfection following successful direct-acting antiviral therapy among patients attending a multidisciplinary treatment centre for people who use drugs in Zurich, Switzerland. Int J Drug Policy 2021;96:103434. [PMID: 34511311 DOI: 10.1016/j.drugpo.2021.103434] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]